​

89bio Stock (NASDAQ:ETNB)

ForecastRevenueOwnershipFinancialsChart
89bio by TradingView

Previous Close

$9.01

52W Range

$5.99 - $16.63

50D Avg

$7.85

200D Avg

$8.32

Market Cap

$1.03B

Avg Vol (3M)

$1.64M

Beta

0.98

Div Yield

-

ETNB Company Profile

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

70

IPO Date

Nov 11, 2019

Website

ETNB Performance

ETNB Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-151.20M$102.25M$-89.74M
Net Income$-142.19M$-102.03M$-90.12M
EBITDA$-151.20M$-102.25M$-89.74M
Basic EPS-$-2.93$-4.48
Diluted EPS-$-2.93$-4.48

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
HEPAHepion Pharmaceuticals, Inc.
TERNTerns Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
VKTXViking Therapeutics, Inc.
STOKStoke Therapeutics, Inc.
ACLXArcellx, Inc.
DAWNDay One Biopharmaceuticals, Inc.
PLRXPliant Therapeutics, Inc.
XFORX4 Pharmaceuticals, Inc.
AKROAkero Therapeutics, Inc.
HOOKHOOKIPA Pharma Inc.
TGTXTG Therapeutics, Inc.
INZYInozyme Pharma, Inc.
ABOSAcumen Pharmaceuticals, Inc.
MDGLMadrigal Pharmaceuticals, Inc.